Summary
Modified citrus pectin (MCP) is a specialized form of pectin, a complex carbohydrate naturally found in the cell walls of fruits and vegetables, especially citrus fruits such as oranges, lemons and grapefruit. Through a specific modification process, the molecular weight and the degree of esterification in pectin are reduced, which makes MCP more easily absorbable in the body. This modification gives MCP unique therapeutic properties that have made it a focus area in research and clinical practice.
Pectin in its natural form is known for its prebiotic properties and its ability to regulate blood sugar and cholesterol levels. Modified citrus pectin stands out by being far more bioavailable, which gives it a number of health benefits related to detoxification, immune modulation, anti-cancer properties, as well as protection of the heart, brain, intestines, kidneys and liver. MCP's ability to inhibit galectin-3, a protein that plays a role in inflammation, fibrosis and tumor growth, is one of the main mechanisms behind its therapeutic effects.
Benefits and effects
Detoxification of heavy metals
MCP acts as a natural chelator that helps the body remove harmful heavy metals such as lead, mercury, arsenic and cadmium. Studies show that MCP increases the excretion of lead in children with elevated levels without affecting essential minerals such as calcium, magnesium and zinc. In addition, MCP has been shown to contribute to the elimination of uranium, which is particularly relevant for people exposed to environmental toxins from industry and agriculture.
The mechanism behind this detoxification is MCP's ability to selectively bind to toxic metals in the gut and prevent their reabsorption, facilitating safe excretion through feces and urine. This process makes MCP an effective and gentle alternative to synthetic chelators, which can often lead to the loss of essential nutrients.
Anticancer properties
MCP has been studied for its anticancer properties, particularly in relation to prostate cancer, breast cancer, lung cancer and gastrointestinal cancer. Research shows that MCP inhibits tumor growth, reduces metastases and increases sensitivity to chemotherapy.
In one study, it was shown that MCP could reduce PSA levels in patients with prostate cancer, indicating a slower progression of the disease. Another preclinical study showed that MCP inhibited the growth of breast cancer cells in animal models. MCP has also been shown to block galectin-3, which is involved in tumor cell adhesion and metastasis.
Support for the immune system
MCP has immunomodulatory effects that contribute to a balanced immune response. Studies show that MCP can increase the activity of natural killer cells (NK cells) and strengthen the body's defenses against infections. In addition, MCP has been shown to reduce systemic inflammation, which may be beneficial for people with autoimmune conditions.
A preclinical study showed that MCP could reduce inflammatory markers associated with sepsis-induced kidney damage, as well as reduce oxidative stress and neuroinflammation in diabetes.
Cardiovascular diseases
MCP has been shown to have protective effects on the heart and blood vessels, mainly through its ability to inhibit galectin-3, a key factor in the development of cardiac fibrosis and atherosclerosis. A study published in European Heart Journal showed that MCP reduced inflammation and fibrotic changes in the myocardial tissue, which improved heart function.
In addition, MCP has been shown to reduce LDL cholesterol and triglycerides, thereby reducing the risk of cardiovascular disease.
Technical specifications
MCP is produced by enzymatic or pH-modified degradation of natural pectin from citrus fruits. This results in a low molecular weight (<15 kDa) and a high proportion of galacturonic acid (>85%), which ensures maximum bioavailability and effectiveness.
Disclaimer and reservations
Use of MCP should be done in consultation with qualified healthcare personnel. Keep out of the reach of children. Uno Vita AS does not claim that MCP can cure disease.
Freedom of expression and right to information
Uno Vita reserves the right to share publicly available research on health and wellness technologies in accordance with:
-
UN Human Rights (1948), Article 19: The right to freedom of opinion and expression.
-
International Covenant on Civil and Political Rights (1966), Article 19: Freedom to seek, receive and impart information.
-
Norwegian Constitution § 100: Protection of freedom of expression.
-
The United States' First Amendment: Protection of freedom of speech against government interference.
References
-
Eliaz, I. (2006). Clinical Toxicology, 44(2), 101-109.
-
Petersen, G.M., et al. (2018). Toxicology Reports, 5, 17-25.
-
Yan, J., & Katz, A. (2010). Journal of Cancer Research and Therapeutics, 6(3), 201-205.
-
Guess, B.W., et al. (2003). Journal of Urology, 169(2), 405-410.
-
Inohara, H., et al. (2002). Cancer Research, 62(7), 1973-1979.
-
Gunning, A.P., et al. (2013). Biochimica et Biophysica Acta, 1830(11), 4063-4075.
-
Jackson, C.L., et al. (2007). Immunology Letters, 112(2), 120-125.
-
Henderson, N.C., et al. (2013). Hepatology, 58(3), 1082-1095.
-
Wang, Y. et al. (2018). Translational Medicine, 10(4), 451-465.
-
Martinez-Martinez, E., et al. (2015). Cardiovascular Research, 107(3), 307-317.
-
Yu, L., et al. (2014). European Heart Journal, 35(24), 1606-1614.
-
Viskovic, K., et al. (2020). Diabetes & Metabolism, 46(1), 13-19.
